Focus on the 7th WCIFIT | Multiple Chongqing-Based Enterprises to Showcase Pioneer Products and Innovative Achievements at the Fair

The 7th Western China International Fair for Investment and Trade (WCIFIT) will be held in Chongqing from May 22 to May 25. On May 20, it was learned from Liangjiang New Area that several life and health enterprises from Chongqing will participate in the fair with a number of domestically pioneering products and cross-border innovative achievements.

For example, as one of the leading enterprises in China's artificial heart field, EVAHEART will bring the country's first approved artificial heart product, the "EVAHEART Artificial Heart," to the exhibition.

It is reported that this product is an artificial heart designed for long-term treatment and features bionic pulsatile blood flow technology. It has already been applied in countries and regions such as Japan, Europe, and the United States.

The production line of EVAHEART in Shuitu New City, Liangjiang New Area. (Captured by Zhang Jinhui)

Meanwhile, during the WCIFIT, Chongqing Xishan Science & Technology Co., Ltd. will showcase six products and solutions, including surgical power devices and a breast lesion rotational biopsy system.

Among them, the breast lesion rotational biopsy system is suitable for the biopsy of breast lesions and minimally invasive treatment of benign lesions. It enables "continuous adjustment of the sampling window within a 5mm-30mm range" and represents China's first fully independently developed breast rotational biopsy system, with over 30 patents filed.

This product has also become the first domestically produced breast rotational biopsy brand to be exported overseas. Multiple VABB training centers have been established abroad, creating an international academic exchange platform.

Breast lesion rotational biopsy system (Photograph courtesy of the interviewed enterprise)

Additionally, as a representative multinational enterprise based in Chongqing's Liangjiang New Area, Danaher will make its debut at the WCIFIT, bringing cutting-edge solutions from its operating companies in three frontier fields: cell and gene therapy, organoids, and synthetic biology.

It is reported that in the field of cell and gene therapy, among the 11 CAR-T cell therapies currently approved for global marketing, six originate from China, and all these six CAR-T therapies utilize products and technologies from Cytiva, a Danaher company.

According to the introduction, CAR-T therapy represents an innovative immunotherapy approach that involves extracting T cells from patients, genetically modifying these cells to endow them with the capability to "recognize and attack" cancer cells. These "soldier cells" are then reinfused into the patient's body to achieve precise targeting of specific cancer cells.

Simultaneously, several other technologically advanced medical devices will also be showcased, including Chongqing Moffy Innovation Technology Co., Ltd. of China's semi-automatic Heimlich maneuver first-aid device (China's first and globally pioneering product), Chongqing Guoke Yichuang Technology Development Co., Ltd.'s deep-layer high-energy photon therapy system, and Miconvey's ultrasonic soft tissue surgical equipment.  

Source: New Chongqing - Chongqing Daily